Notice: Could not load module: 'blacklist' (required module files not found) in /kunden/228602_82418/webseiten/gmp/gmpupdate.swhosting6.de/modules/seitbox/SeitboxModule.php on line 700

Warning: Warning: output buffer is not empty, but dispatching and rendering content has not been started yet. in /kunden/228602_82418/webseiten/gmp/gmpupdate.swhosting6.de/library/Seitbox/bootstrap.php on line 170
GMP News - Good Manufacturing Practices - GMP Newsletter
  • gmp-verlag.de
  • GMP MANUAL Login
  • Shopping cart
Stay informed!

If you’d like to be regularly informed of the latest developments at Good Manufacturing Practices

 

>>> REGISTER for our free GMP Newsletter LOGFILE

Image

TOP 5 GMP Downloads

1. Quality Agreement
Defines framework conditions and processes between contract givers and contract acceptors in order to meet mandatory quality criteria.

 

2. GDP Audit Checklist
More than 700 questions with reference to regulations for preparing and carrying out GDP audits.

 

3. GMP Audit Checklist
The GMP Audit Checklist works great for both sides - the auditor and the inspected company.

 

4. Technical Agreement
and Delimination of Pharmaceutical Responsibilities.

 

5. A Process Approach to Pharmaceutical Quality Systems
A Guide to ICH Q10 Compliance

 

Your benefits:

> no shipping costs
> no waiting period: if you choose payment by credit card you will receive an email with the download information immediately after payment.

 

>>> Click here to find more Downloads!

News about GMP/cGMP

2014-12-09

The EMA has published the final version of the „Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities”. The document was long expected and aims to recommend an approach for deriving a scientifically based threshold value for individual active substances to be applied for risk identification.

 
2014-12-03

A biosimilar is a biological medicinal product that contains a version of the active substance of an already authorised original biological medicinal product (reference medicinal product) in the EEA. The EMA has published a revised version of the guideline "Guideline on similar biological medicinal products". It outlines the general principles to be applied for similar biological medicinal products (also known as biosimilars) as referred to in Directive 2001/83/EC and includes the following categories:

 
2014-11-21

Officials of Australia and New Zealand have confirmed the plan to stop the development of the joint regulatory authority ANZTPA. The decision was taken following a comprehensive review of progress and assessment of the costs and benefits to each country.

 
2014-11-21

This month representatives of the FDA have met with their cross-agency team from the EMA, the European Commission and GMP experts form European Union Member States in London, in order to make progress on mutual reliance on GMP inspections. The event was the first face-to-face meeting of both complete teams to discuss how EMA and FDA can collaborate in the field of inspections.

 
2014-11-14

The FDA has published the following two updated lists of guidelines:

 
2014-11-11

ISPE released its Drug Shortages Prevention Plan during the 2014 Annual Meeting in Las Vegas, Nevada. ISPE developed the plan in response to global regulatory interest in preventing drug shortages due to manufacturing and quality issues. The plan addresses shortages at both the product and process levels. It lays out how industry can best prevent drug shortages by identifying the root causes of supply disruptions and creating a quality culture that will ensure a robust, resilient and reliable supply of medications to patients worldwide.

 
2014-10-31

MHRA just published inspection trend data from 2013. The report has been presented in a revised format, following comments from a stakeholder focus group. In addition to 2013 inspection deficiency data, the report also includes longer term trends in ‘top 10 deficiencies’ and highlights areas for continued focus.

 
2014-10-28

This month the EMA released a “Reflection paper in the requirements for selection and justification of starting materials for the manufacture of chemical active substances”. It aims to clarify some of the expectations of EU competent authorities arising from the guidance found in ICH Q11 regarding the information to be submitted in marketing authorisation dossiers to justify the selection of starting materials.

 
 
Page 4/54    1   2   3   4   5   6   7   8   9   10